Quantcast
Last updated on April 18, 2014 at 17:24 EDT

Latest Influenza research Stories

2012-11-14 04:22:46

BLUE BELL, Pa., Nov. 14, 2012 /PRNewswire/ -- Inovio Pharmaceuticals, Inc. (NYSE MKT: INO) has expanded its existing license agreement with the University of Pennsylvania (UPenn), adding worldwide rights to technology and intellectual property for novel synthetic vaccines against cancer, infectious diseases and potential biodefense pathogens. These technologies were developed by UPenn Professor David B. Weiner and collaborators. Dr. Weiner is a pioneer in the field of DNA vaccines, and...

2012-11-02 11:26:18

SWIFTWATER, Pa. and BALTIMORE, Nov. 2, 2012 /PRNewswire/ -- Sanofi Pasteur will bring its Fluzone(®) Intradermal Vaccine Coop de Quill VacciNation Tour to Baltimore on Friday, Nov. 2, as part of its cross-country efforts to raise awareness about the seriousness of influenza and the various vaccine options that are available for adults 18 through 64 years of age this flu season. In an effort to help improve flu immunization rates, Sanofi Pasteur's Fluzone Intradermal Vaccine Coop de Quill...

2012-10-31 19:21:51

Canadians urged to protect themselves for the coming flu season. Video: B-Roll - October 31, 2012: John Dorsey Head, Vaccines and Diagnostics at Novartis Pharmaceuticals Canada Inc. receiving Agriflu(®) influenza vaccine. Video available here. DORVAL, QC, Oct. 31, 2012 /CNW/ - Novartis Pharmaceuticals Canada Inc. has announced it is resuming distribution of two seasonal influenza vaccines in Canada, Fluad(®) and Agriflu(®), following the announcement by Health Canada...

2012-10-22 11:25:37

NES ZIONA, Israel, October 22, 2012 /PRNewswire/ -- BiondVax Pharmaceuticals Ltd. (TASE: BNDX) today announced that the Company has passed successfully a 2 day QP GMP audit during which the Company`s manufacturing facility, production process, personnel and quality control procedures were examined in great detail. This demanding certification is a requirement for Companies intending to manufacture a clinical grade product for human trials anywhere in Europe and gives the Company...

2012-10-22 07:30:26

SWIFTWATER, Pa., Oct. 22, 2012 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), presented today an overview of Phase II and Phase III clinical trials for its investigational quadrivalent influenza vaccine (QIV). Three clinical trials have been conducted to evaluate the safety and the immune response to the quadrivalent influenza vaccine in children, adults and the elderly. All three studies demonstrated that the safety and immunogenicity profiles...

2012-10-18 07:26:23

SWIFTWATER, Pa., Oct. 18, 2012 /PRNewswire/ -- Sanofi Pasteur, the vaccines division of Sanofi (EURONEXT: SAN and NYSE: SNY), announced today that it has filed a Supplemental Biologics License Application (sBLA) with the U.S. Food and Drug Administration (FDA) for a quadrivalent formulation of its Fluzone(® ) (Influenza Virus Vaccine). The sBLA file has been accepted by the FDA for full review, and an action date is anticipated in the second quarter of 2013. "The...

2012-10-17 07:27:45

SAN DIEGO, Oct. 17, 2012 /PRNewswire/ -- Pfenex Inc. today announced that the National Institute of Allergy and Infectious Diseases (NIAID) under its Broad Agency Announcement entitled "Vaccine Technologies to Advance Next Generation Anthrax Vaccines" (BAA-NIAID-DMID-NIHAI2010104) has awarded Pfenex a contract to develop an alternative delivery method for Pfenex's recombinant Protective Antigen (rPA)-based anthrax vaccine. NIAID, part of the National Institutes of Health, has made an initial...

2012-10-09 20:40:59

Renowned virus experts address the moratorium on potentially hazardous H5N1 influenza research Last winter, scientists at the University of Wisconsin and Erasmus University (Netherlands) shocked the world by announcing they had developed strains of H5N1 influenza that could easily pass between mammals (ferrets). In nature, H5N1 is extremely lethal (kills nearly 60% of its human cases), but it does not easily spread from person-to-person. Thus, biosafety concerns were raised over the...

2012-10-05 06:24:15

SWIFTWATER, Pa. and SAN FRANCISCO, Oct. 5, 2012 /PRNewswire/ -- Sanofi Pasteur will bring its Fluzone(®) Intradermal Vaccine Coop de Quill VacciNation Tour to San Francisco this Saturday, Oct. 6, as part of its cross-country efforts to raise awareness about the seriousness of influenza and the various vaccine options that are available for adults 18 through 64 years of age this flu season. In an effort to help improve flu immunization rates, Sanofi Pasteur's Fluzone Intradermal Vaccine...

2012-09-24 06:27:21

SWIFTWATER, Pa. and KIRKLAND, Wa., Sept. 24, 2012 /PRNewswire/ -- Sanofi Pasteur will bring its Fluzone(®) Intradermal Vaccine Coop de Quill VacciNation Tour to Seattle on Monday, Sept. 24, as part of its cross-country efforts to raise awareness about the seriousness of influenza and the various vaccine options that are available for adults 18 through 64 years of age this flu season. In an effort to help improve flu immunization rates, Sanofi Pasteur's Fluzone...